In 1994, the identification of BRCA1 marked a turning point in medicine: For the first time, a significant portion of the hereditary breast and ovarian cancer risk could be explained genetically – a breakthrough to which researchers like Mary-Claire King made substantial contributions. Since then, precision prevention has gained momentum: Women can today better quantify their personal risk and tailor preventive measures. The goal is clear: to live healthier for longer, with more certainty and less randomness.

Genetic tests search for germline variantsinherited changes in the genetic material that are present in all body cells that increase the risk of certain diseases. Famous among them are BRCA1/2tumor suppressor genes; pathogenic variants increase the risk of breast and ovarian cancer, but other genes like PALB2partner gene of BRCA2, increases breast cancer risk, CHEK2DNA repair gene with moderate risk contribution, or mismatch repair genesgenes that control DNA repair; defects promote endometrial and colorectal cancer also play a role. Importantly, a predisposition is not a destiny but a risk signal. Results are interpreted in the context of family historydocumented diseases of close relatives, lifestyle, and validated risk models (e.g., Tyrer–Cuzick). Direct-to-consumer tests often provide incomplete data; clinically validated tests with genetic counseling remain the gold standard ^[1].

Those who know their genetic profile can plan prevention more accurately. In an OB/GYN initiative, most tested women did not carry a pathogenic mutation, yet more than a third still reached a ≥20% lifetime risk for breast cancer through combined risk models – a threshold that justifies more intensive early detection ^[2]. For carriers of high-risk variants like BRCA1/2, the focus shifts from screening to prevention: As ovarian cancer screenings are of limited effectiveness, chemopreventive approaches and prophylactic interventions are at the center of a risk-adapted strategy ^[3]. In specific syndromes like hereditary medullary thyroid carcinoma, early prophylactic thyroidectomy can even prevent the disease – albeit at the cost of lifelong hormone substitution and with careful benefit-risk assessment ^[4].

A prospective quality initiative in gynecological practices demonstrated that integrating routine history-based risk assessment and panel tests refines management: Although pathogenic findings were rare (3.2%), combined scores identified a substantial group with high lifetime risk – crucial for personalized preventive decision-making ^[2]. A narrative systematic review of hereditary gynecological cancer risks emphasizes a precision prevention architecture: expanded germline testing and universal mismatch repair screening improve the identification of carriers; due to the limited sensitivity of conventional monitoring, risk-reducing surgeries, hormone strategies, and, prospectively, liquid biopsy come into focus, always embedded in multidisciplinary counseling that considers fertility and menopausal health ^[3]. Another review on preventive thyroid surgery shows how genotype-based risk classification determines the timing of interventions and provides evidence for curative prevention in RET mutations – it also illustrates that the expansion of the intervention can increase morbidity, making individual indications central ^[4].

- Create a personal genetic risk profile for breast and ovarian cancer with your doctor: combine family history, clinically validated panel tests, and risk models (e.g., Tyrer–Cuzick) to clarify thresholds for more intensive screening ^[2].
- Explore preventive options for high risk: discuss risk-reducing surgeries (e.g., salpingo-oophorectomy for BRCA1/2) and pharmacological prevention; ensure that fertility, menopause management, and personal preferences are included in interdisciplinary consultations ^[3]. In cases of RET mutations, an early prophylactic thyroidectomy can be curative – but only after specialized counseling ^[4].
- Share relevant results within the family and support cascade testing: informed relatives take advantage of preventive opportunities sooner; studies show high communication rates and potential for increased cascade testing through structured genetic counseling ^[5].
- Seek professional support for interpretation: avoid misinterpretations (e.g., variants of uncertain significance) and unnecessary procedures; genetic counseling reduces documented errors and consequential harm ^{[6] [7]}.
- Prefer clinically validated tests over direct-to-consumer offerings and clarify funding and insurance issues early on. Be aware of possible coverage gaps for risk-reducing interventions and inform yourself about protection against genetic discrimination in your country ^{[1] [8]}.

Genetic tests are not oracles but navigation systems: they show where prevention has the greatest leverage. Those who translate knowledge into action – with informed counseling, a clear plan, and family involvement – gain the rare combination of serenity and control over their own health.